Of course, any possible approach to evaluate the efficacy of 4-AP therapy on KCNA2 patients of the GoF or mixed GoF/LoF functional subclass, should consider outcome measures such as Scale for Assessment and Rating of Ataxia (SARA and SARA@home) and gait analysis tools [42,43], and monitoring of seizure frequency through consecutive EEGs and patient-compiled questionnaires. The gene discussed is KCNA2; the disease is Ataxia.